TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32562763

Group type: EXPERIMENTAL
Intervention: Arthroscopic biceps tenodesis (BT)
Number of subjects: 3635

Group type: COMPARATOR
Intervention: Open biceps tenodesis (BT)
Number of subjects: 3635

Group type: EXPERIMENTAL
Intervention: Concomitant subacromial decompression
Number of subjects: 3635

Group type: EXPERIMENTAL
Intervention: Concomitant distal clavicle resection
Number of subjects: 3635

Group type: EXPERIMENTAL
Intervention: High volume surgical facilities
Number of subjects: 3635
Study: 35488009

Group type: EXPERIMENTAL
Intervention: TIR intervention group (routine nursing follow‐up and comprehensive nursing intervention based on TIR)
Number of subjects: 140
Study: 34188053

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by definitive chemoradiotherapy (CRT)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Chemoradiotherapy (CRT) alone
Number of subjects: 110
Study: 32200585

Group type: EXPERIMENTAL
Intervention: Exercise and Diet (EXD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diet (DI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Exercise (EX)
Number of subjects: 30
Study: 35453054

Group type: EXPERIMENTAL
Intervention: Mesh placement (experimental group, n = 24)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (no mesh, n = 32)
Number of subjects: 56
Study: 33039717

Group type: EXPERIMENTAL
Intervention: Experimental external nasal dilator (END)
Number of subjects: 71
Study: 35537291

Group type: EXPERIMENTAL
Intervention: Transverse blunt extension of the uterine incision during cesarean section
Number of subjects: 0

Group type: COMPARATOR
Intervention: Longitudinal blunt extension of the uterine incision during cesarean section
Number of subjects: 0
Study: 33671166

Group type: EXPERIMENTAL
Intervention: Unripe banana flour (UBF) 21 g/day
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (waxy corn starch 12 g/day)
Number of subjects: 43
Study: 32852460

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Phytoestrogens (75 mg soy isoflavones, BID)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Hormone Therapy (0.3 mg conjugated equine oestrogens plus 1.5 mg medroxyprogesterone acetate)
Number of subjects: 61
Study: 35182048

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) technique, conducted in six sessions through Sky Room, three times a week
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 126
Study: 32620163

Group type: COMPARATOR
Intervention: Arm A: Pegylated liposomal doxorubicin (PLD 20 mg/m2 intravenously every 2nd week) + cyclophosphamide (50 mg per day, first 2 weeks in each 4 week cycle)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Arm B: Pegylated liposomal doxorubicin (PLD) + cyclophosphamide + ipilimumab (1 mg intravenously every 6th week) + nivolumab (240 mg intravenously every 2nd week)
Number of subjects: 75
Study: 35837209

Group type: EXPERIMENTAL
Intervention: LiSi surface treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glass-ceramics (Control)
Number of subjects: 60
Study: 34924363

Group type: EXPERIMENTAL
Intervention: Childbirth massage programme
Number of subjects: 479

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 479
Study: 34968876

Group type: EXPERIMENTAL
Intervention: Participation in a randomized controlled trial of lateral episiotomy or no episiotomy in vacuum extraction
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Use of episiotomy in vacuum extractions
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Illustrated episiotomies
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Correctly drawn episiotomies
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Ranking of episiotomy importance
Number of subjects: 384
Study: 32272659

Group type: EXPERIMENTAL
Intervention: OM3-sn-1(3)-monoacylglycerol (OM3-MAG) at 2.9 g/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: OM3-ethyl ester at 3.1 g/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OM3-free fatty acids (OM3-FFA) at 3.2 g/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: OM3-triacylglycerols (OM3-TAG) at 1.2 g/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: OM3 at 1.0 g/day
Number of subjects: 0
Study: 35543647

Group type: EXPERIMENTAL
Intervention: Psychologically informed physical therapy (PIPT)
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1250
Study: 33047405

Group type: EXPERIMENTAL
Intervention: Localized 308-nm excimer light
Number of subjects: 36

Group type: COMPARATOR
Intervention: Targeted 311-nm NB-UVB
Number of subjects: 36
Study: 32577026

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study: 36192005

Group type: EXPERIMENTAL
Intervention: UV‐modified lamps with UV‐on
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo lamps with UV switched off
Number of subjects: 20
Study: 34160125

Group type: EXPERIMENTAL
Intervention: In-office gel with bioactive nanoparticles (n-Bm)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control - only in-office gel
Number of subjects: 66
Study: 32770859

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 35099991

Group type: EXPERIMENTAL
Intervention: PE diagnostic strategy + usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 34314304

Group type: EXPERIMENTAL
Intervention: Food feature posts
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Macronutrient posts
Number of subjects: 15
Study: 32093657

Group type: EXPERIMENTAL
Intervention: Vitamin D 2000 IU/d
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 37605110

Group type: EXPERIMENTAL
Intervention: Multimodal machine‐based exercise training programme (twice weekly for 45-60 min over six months)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Multimodal machine‐based exercise training programme
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study: 33864337

Group type: EXPERIMENTAL
Intervention: ≤20 W with 20 W laser device (group 1)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: ≤20 W with 30 W laser device (group 2)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: >20 W with 30 W laser device (group 3)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 30 W laser device (groups 2 and 3)
Number of subjects: 204

Group type: COMPARATOR
Intervention: 20 W laser device (group 1)
Number of subjects: 204
Study: 35714294

Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention (7 sessions over 3 weeks)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 122
Study: 32575482

Group type: EXPERIMENTAL
Intervention: MyHealthAvatar-Diabetes smartphone app for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study: 35197248

Group type: EXPERIMENTAL
Intervention: Enhanced online injury prevention programme
Number of subjects: 4050

Group type: COMPARATOR
Intervention: Regular preparation for the running event (Control)
Number of subjects: 4050
Study: 32386747

Group type: EXPERIMENTAL
Intervention: 30 µg GMZ2-CAF01
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 100 µg GMZ2-CAF01
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 100 µg GMZ2-alum
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control vaccine (rabies vaccine)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All GMZ2 vaccinated participants
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Treg frequencies on D0 or on D84, and Breg frequency on D84
Number of subjects: 50
Study: 34780323

Group type: EXPERIMENTAL
Intervention: Surgical fixation (open spinal surgery or minimally invasive stabilisation surgery)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conservative management (mobilisation with or without a brace)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recruitment rate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Qualitative study
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Surgeon willingness to randomise
Number of subjects: 12
Study: 35427495

Group type: EXPERIMENTAL
Intervention: 4-month anti-TNF therapy and surgical closure
Number of subjects: 94

Group type: COMPARATOR
Intervention: Anti-TNF therapy for 1 year
Number of subjects: 94
Study: 34648734

Group type: EXPERIMENTAL
Intervention: Intramuscular long-acting cabotegravir (600 mg) and rilpivirine (900 mg) every 8 weeks
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Intramuscular long-acting cabotegravir (400 mg) and rilpivirine (600 mg) every 4 weeks
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Confirmed virological failure in every 8-week group
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Confirmed virological failure in every 4-week group
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Injection site reactions in every 8-week group
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Injection site reactions in every 4-week group
Number of subjects: 1045
Study: 32819728

Group type: EXPERIMENTAL
Intervention: 1 g intra-articular tranexamic acid (TXA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2 g intra-articular tranexamic acid (TXA)
Number of subjects: 100
Study: 33638108

Group type: EXPERIMENTAL
Intervention: 3D endovision system
Number of subjects: 139

Group type: COMPARATOR
Intervention: 4K endovision system
Number of subjects: 139
Study: 33952358

Group type: EXPERIMENTAL
Intervention: Models 1-7 (weighted sum scores and unweighted sum score models)
Number of subjects: 1722

Group type: COMPARATOR
Intervention: Null model (mean post-baseline BDI-II score)
Number of subjects: 1722
Study: 35043484

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg plus doxazosin 2 mg once daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tolterodine 4 mg plus doxazosin 2 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study: 34176234

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 40
Study: 33661283

Group type: EXPERIMENTAL
Intervention: Hyper-reflectivity
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ellipsoid zone (EZ)-loss
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lesion size for hyper-reflectivity
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity (BCVA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Reading speed
Number of subjects: 52
Study: 32035998

Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus casei DN114001 combined with two regular yoghurt bacterial strains)
Number of subjects: 1127

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 1127
Study: 36408831

Group type: EXPERIMENTAL
Intervention: Occupational Therapy Driving Intervention (OT‐DI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Traffic Safety Education (TSE)
Number of subjects: 42
Study: 33118677

Group type: EXPERIMENTAL
Intervention: Isobutylamido thiazolyl resorcinol (ITR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 24
Study: 32414676

Group type: EXPERIMENTAL
Intervention: Pharmacomechanical catheter-directed thrombolysis (PCDT)
Number of subjects: 451
Study: 35346148

Group type: EXPERIMENTAL
Intervention: Educational program based on the Health Belief Model (HBM) with five consecutive weekly sessions
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Educational program based on the Health Belief Model (HBM)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Routine education delivered by the dental clinic (Control)
Number of subjects: 112
Study: 32767288

Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle biopsy (FNB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: EUS-guided fine-needle aspiration (FNA)
Number of subjects: 50
Study: 33541690

Group type: EXPERIMENTAL
Intervention: Visual teaching aid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 30
Study: 32544221

Group type: EXPERIMENTAL
Intervention: Crushed and suspended elbasvir/grazoprevir
Number of subjects: 11

Group type: COMPARATOR
Intervention: Whole tablet elbasvir/grazoprevir
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 11
Study: 35933730

Group type: EXPERIMENTAL
Intervention: CSL112 (2, 4, or 6 g)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CSL112 (6 g)
Number of subjects: 34
Study: 32945632

Group type: EXPERIMENTAL
Intervention: Avelumab plus best supportive care
Number of subjects: 700

Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 700
Study: 35555129

Group type: EXPERIMENTAL
Intervention: Home-based leg heat therapy (HT), n=15
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control treatment (CON), n=14
Number of subjects: 34
Study: 35610590

Group type: EXPERIMENTAL
Intervention: AVATAR therapy
Number of subjects: 20
Study: 33106968

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 300–400 U
Number of subjects: 468

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 468
Study: 36122439

Group type: EXPERIMENTAL
Intervention: Prompt Mental Health Care (PMHC)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 463
Study: 33504865

Group type: EXPERIMENTAL
Intervention: Community health workers (CHWs) treatment for SAM
Number of subjects: 364

Group type: COMPARATOR
Intervention: Outpatient therapeutic care (OTC)
Number of subjects: 364
Study: 32087417

Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33728436

Group type: EXPERIMENTAL
Intervention: Weekly carboplatin plus nab-paclitaxel
Number of subjects: 166

Group type: COMPARATOR
Intervention: Daily low-dose carboplatin
Number of subjects: 166
Study: 36100893

Group type: EXPERIMENTAL
Intervention: Nomograms for recurrence-free survival (RFS)
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Nomograms for overall survival (OS)
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Nomograms compared to conventional staging systems
Number of subjects: 1003
Study: 33843948

Group type: EXPERIMENTAL
Intervention: Self-directed web-based strengthening exercise and physical activity program supported by automated behavior-change text messages
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group with access to a custom-built website with information on OA and exercise
Number of subjects: 206
Study: 32116285

Group type: EXPERIMENTAL
Intervention: Deep yogic breathing, listening to religious hymns, listening to flute music
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 400
Study: 36260986

Group type: EXPERIMENTAL
Intervention: Worksite-based intensive lifestyle therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34156730

Group type: EXPERIMENTAL
Intervention: 1 Hz TNT
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 5 Hz TNT
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 15 Hz TNT
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (5 Hz and 15 Hz)
Number of subjects: 33
Study: 32761638

Group type: EXPERIMENTAL
Intervention: 12-week daily reminders
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78
Study: 35357866

Group type: EXPERIMENTAL
Intervention: 14-session parenting program
Number of subjects: 387

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 387
Study: 36057149

Group type: EXPERIMENTAL
Intervention: Scenario simulations of acute and critical care
Number of subjects: 88
Study: 33162795

Group type: EXPERIMENTAL
Intervention: Brief advisory session plus measuring exhaled CO
Number of subjects: 122

Group type: COMPARATOR
Intervention: Brief advisory session (control)
Number of subjects: 122
Study: 32624013

Group type: EXPERIMENTAL
Intervention: HeadGear smartphone app (30-day behavioural activation and mindfulness intervention)
Number of subjects: 2271

Group type: COMPARATOR
Intervention: Attention-control app (30-day mood monitoring component)
Number of subjects: 2271
Study: 33795571

Group type: EXPERIMENTAL
Intervention: HU-014
Number of subjects: 290

Group type: COMPARATOR
Intervention: OnabotulinumtoxinA
Number of subjects: 290
Study: 32785233

Group type: EXPERIMENTAL
Intervention: Vegan diet during Lenten fasting
Number of subjects: 75

Group type: COMPARATOR
Intervention: Post-Lenten omnivore diet
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Vegan diet in females
Number of subjects: 75
Study: 36416980

Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream
Number of subjects: 0
Study: 33300952

Group type: EXPERIMENTAL
Intervention: RNA test (Afirma genomic sequencing classifier)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: DNA-RNA test (ThyroSeq v3 multigene genomic classifier)
Number of subjects: 346

Group type: COMPARATOR
Intervention: RNA test (Afirma gene expression classifier)
Number of subjects: 346

Group type: COMPARATOR
Intervention: DNA-RNA test (ThyroSeq v2 next-generation sequencing)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Surveillance ultrasonography
Number of subjects: 346
Study: 35861823

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 34544403

Group type: EXPERIMENTAL
Intervention: IMARA program
Number of subjects: 525

Group type: COMPARATOR
Intervention: Family-based control program
Number of subjects: 525
Study: 33341312

Group type: EXPERIMENTAL
Intervention: Calcitriol (1 mcg/day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cholecalciferol (50,000 IU/week)
Number of subjects: 54
Study: 32792167

Group type: EXPERIMENTAL
Intervention: Therapeutic agents for human therapy in patients with COVID-19
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of available drugs and prospective therapies
Number of subjects: 60
Study: 35571615

Group type: EXPERIMENTAL
Intervention: Focused psychological intervention combined with standardized pain nursing
Number of subjects: 84

Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 84
Study: 34689451

Group type: EXPERIMENTAL
Intervention: Carica papaya mouthrinse
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chlorhexidine (0.12%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 40
Study: 32776831

Group type: EXPERIMENTAL
Intervention: Pharmaceutical workers
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-pharmaceutical subjects
Number of subjects: 40
Study: 35275213

Group type: EXPERIMENTAL
Intervention: Hannay model
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sleep/wake parameters
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sleep/wake variables
Number of subjects: 29
Study: 33479499

Group type: EXPERIMENTAL
Intervention: minimally processed, plant-based, low-fat diet (10.3% fat, 75.2% carbohydrate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: minimally processed, animal-based, ketogenic, low-carbohydrate diet (75.8% fat, 10.0% carbohydrate)
Number of subjects: 20
Study: 34096413

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous alteplase
Number of subjects: 940

Group type: COMPARATOR
Intervention: Standard-dose intravenous alteplase
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 940

Group type: COMPARATOR
Intervention: Standard blood pressure lowering
Number of subjects: 940
Study: 34988183

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (ONS) 300 mL/day for 4 weeks
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 77
Study: 35589905

Group type: EXPERIMENTAL
Intervention: Patient Decision Aids (PDA)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard (SDM without PDA)
Number of subjects: 151
Study: 33278332

Group type: EXPERIMENTAL
Intervention: M‐NMB, sugammadex 2 mg/kg ABW
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: M‐NMB, sugammadex 2 mg/kg IBW
Number of subjects: 5

Group type: COMPARATOR
Intervention: M‐NMB, neostigmine 5 mg + glycopyrrolate 1 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: D‐NMB, sugammadex 4 mg/kg ABW
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: D‐NMB, sugammadex 4 mg/kg IBW
Number of subjects: 5
Study: 35938345

Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia (IV)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Local anesthesia (LA)
Number of subjects: 50
Study: 33512910

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (1000 mg) and targeted therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Targeted therapy alone
Number of subjects: 60
Study: 32580978

Group type: EXPERIMENTAL
Intervention: Laparoscopic therapy plus propranolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endoscopic therapy plus propranolol
Number of subjects: 40
Study: 36052527

Group type: EXPERIMENTAL
Intervention: 60-day head-down bed rest (HDBR)
Number of subjects: 20
Study: 34490103

Group type: EXPERIMENTAL
Intervention: Adversarial deep-learning-based auto-segmentation model
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual delineation by oncologists (GT)
Number of subjects: 20
Study: 34983775

Group type: EXPERIMENTAL
Intervention: DX1 (dexamethasone 24 mg + placebo)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: DX2 (dexamethasone 24 mg + dexamethasone 24 mg)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Placebo (placebo + placebo)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: DX1 vs Placebo
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: DX2 vs Placebo
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: DX1 vs DX2
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Dexamethasone (one dose)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Dexamethasone (two doses)
Number of subjects: 485
Study: 32059579

Group type: EXPERIMENTAL
Intervention: High frequency resistance training (3 times a week)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low frequency resistance training (1 time a week)
Number of subjects: 42
Study: 34637494

Group type: EXPERIMENTAL
Intervention: Vitamin K1 supplementation (10 mg/d)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149